Press Releases by "Chugai Pharmaceutical Co., Ltd."

• Personnel Changes
  [ Pharmaceuticals | 2015-09-25]
• Contribution of Para-transit Vehicles to Welfare Services
  [ Pharmaceuticals | 2015-09-24]
• NICE Recommends Chugai’s RoACTEMRA
  [ Pharmaceuticals | 2015-09-18]
• Disclosure of Information on Chugai’s 2014 Corporate Activities
  [ Pharmaceuticals | 2015-09-18]
• Anti-Cancer Agent “Avastin
  [ Pharmaceuticals | 2015-09-17]
• Chugai Selected for the Second Consecutive Year for the Dow Jones Sustainability Asia Pacific Index,
  [ Pharmaceuticals | 2015-09-16]
• Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo
  [ Pharmaceuticals | 2015-09-10]
• Chugai’s ALK Inhibitor “Alectinib,” New Drug Application
  [ Pharmaceuticals | 2015-09-09]
• Chugai’s Bispecific Antibody “ACE910” for the Treatment of Hemophilia A Designated as a Breakthrough Therapy by the US FDA
  [ Pharmaceuticals | 2015-09-04]
• Filing of Public Knowledge-Based Application for Immunosuppressant “CellCept
  [ Pharmaceuticals | 2015-08-24]
• Supplemental Approval of New Formulation of Immunosuppressant,
  [ Pharmaceuticals | 2015-08-17]
• Organizational and Personnel Changes
  [ Pharmaceuticals | 2015-07-23]
• Relocation of the Tokyo First Branch
  [ Pharmaceuticals | 2015-07-23]
• F. Hoffmann-La Roche Announces Half Year Results 2015
  [ Pharmaceuticals | 2015-07-23]
• Licensing Agreement for Agent Targeting Prevention of Recurrence of Hepatocellular Carcinoma “Peretinoin”
  [ Pharmaceuticals | 2015-07-14]
• Integration and Reorganization of Overseas Subsidiaries
  [ Pharmaceuticals | 2015-06-25]
• Positive Interim Data from Phase I/II study of Chugai’s Bispecific Antibody "ACE910" Presented at the ISTH 2015 Congress
  [ Pharmaceuticals | 2015-06-23]
• Japanese Study for ACTEMRA
  [ Pharmaceuticals | 2015-06-15]
• Guidebook for Employees
  [ Pharmaceuticals | 2015-05-26]
• Filing of New Drug Application for M8010, a Topical Preparation
  [ Pharmaceuticals | 2015-05-25]

Most Popular: "Chugai Pharmaceutical Co., Ltd."